IMUNON Conference Call Announcement
LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a pioneering clinical-stage biotechnology firm focusing on breakthrough DNA-mediated immunotherapy, is set to host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025. This call will delve into the company’s financial results for the third quarter ending September 30, 2025, while providing a thorough update on their clinical development program centered around IMNN-001, a novel DNA-based interleukin-12 (IL-12) immunotherapy.
How to Join the Call
Individuals interested in participating can dial in at 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) to join the IMUNON Third Quarter 2025 Financial Results Conference Call. For those unable to join via phone, a live webcast will also be accessible through the company’s website.
Replay Accessibility
For those wishing to hear the discussion again, the call will be archived and available for replay until November 27, 2025. The replay can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free), or 412-317-0088 (International Toll) using the replay access code 4592282. Additionally, an audio replay will be available for 90 days on the company’s website.
About IMUNON
IMUNON is dedicated to developing innovative treatments that engage the body’s intrinsic capabilities, delivering safe, effective, and long-lasting responses to a diverse range of diseases. Their approach stands in sharp contrast to traditional treatments. Currently, the company is advancing its non-viral DNA technology across various therapeutic modalities.
Therapeutic Modalities
The first modality, TheraPlas, is engineered for the gene-based delivery of cytokines and other therapeutic proteins to fight solid tumors where immune response is particularly beneficial. Meanwhile, the second modality, PlaCCine, focuses on the gene delivery of viral antigens that trigger robust immune responses.
Lead Clinical Program
IMUNON's flagship clinical program is IMNN-001, designed specifically for the localized treatment of advanced ovarian cancer. This therapy has successfully navigated several clinical trials, including a Phase 2 trial known as OVATION 2, and is currently in the midst of a Phase 3 trial called OVATION 3. IMNN-001 operates by instructing the body to generate powerful, cancer-targeting molecules, such as interleukin-12 and interferon gamma, directly at the tumor site.
COVID-19 Initiatives
In addition to its cancer-focused initiatives, IMUNON has successfully completed dosing in its first human trial of a COVID-19 booster vaccine, designated IMNN-101. The company remains committed to pushing the boundaries of plasmid DNA technology, whether through direct initiatives or strategic partnerships, to meet the challenges of hard-to-treat conditions.
Looking Ahead
As the company gears up for its upcoming conference call, IMUNON is set to share more exciting developments in its mission to provide innovative therapeutic options. Stakeholders, investors, and interested parties are encouraged to join and learn about the strides the company has made.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to present IMUNON's financial outcomes for the third quarter of 2025 and update stakeholders on the clinical development program of IMNN-001.
How can I access the replay of the conference call?
The conference call will be archived, and interested listeners can access it until November 27, 2025, using the specified replay codes.
What innovative treatments is IMUNON developing?
IMUNON develops therapies utilizing non-viral DNA technology, focusing on cancer treatments and COVID-19 vaccines, emphasizing the body’s immune response mechanisms.
What is the significance of IMNN-001?
IMNN-001 is a key therapy designed for the localized treatment of advanced ovarian cancer, demonstrating the potential to engage the body’s immune system effectively.
How can I find more information about IMUNON?
For additional details, you can visit the official IMUNON website, which provides a comprehensive overview of the company's current projects and future endeavors.
